Article | Open | Published:

Rapid control of pandemic H1N1 influenza by targeting NKT-cells

Scientific Reports volume 6, Article number: 37999 (2016) | Download Citation


Swine influenza A viruses (IAV) are a major cause of respiratory disease in pigs and humans. Currently approved anti-influenza therapies directly target the virus, but these approaches are losing effectiveness as new viral strains quickly develop drug resistance. To over come this challenge, there is an urgent need for more effective antiviral drugs. Here we tested the anti-influenza efficacy of the invariant natural killer T (NKT) cell superagonist, α-galactosylceramide (α-GalCer), which stimulates a wide array of anti-viral immune responses. We show that intranasal but not systemic administration of α-GalCer to piglets infected with pandemic A/California/04/2009 (CA04) H1N1 IAV ameliorated disease symptoms and resulted in the restoration of weight gain to the level of uninfected pigs. Correspondingly, viral titers in the upper-and lower-respiratory tract were reduced only in piglets that had received intranasal α-GalCer. Most significantly, lung inflammation as a consequence of virus persistence was largely prevented when NKT-cells were targeted via the respiratory route. Thus, targeting mucosal NKT-cells may provide a novel and potent platform for improving the course of disease in swine infected with seasonal and pandemic influenza viruses, and leads to the suggestion that this may also be true in humans and therefore deserves further study.


Swine influenza (SI) is an acute respiratory disease of pigs caused by three subtypes of influenza A viruses (IAV), H1N1, H1N2, and H3N21. Infections often lead to additional respiratory diseases, resulting in substantial economic losses for pork producers2. The risk of SI outbreaks continues to increase due to the accelerating pace at which swine IAVs are evolving1. Besides implementing strict biosecurity measures, vaccination is the most effective strategy to prevent SI infections. However, current swine influenza vaccines do not provide protective immunity for different IAVs even within the same virus subtype and there is often insufficient time to produce and distribute vaccines against emerging strains3,4. These shortcomings contribute to why millions of pigs continue to become infected with swine IAVs every year. Unfortunately, there are no available treatments for pigs already infected with IAVs, which is greatly needed for limiting IAV transmission and reducing production losses.

Of note, swine are susceptible to both human and avian influenza viruses and serve as a mixing vessel for the reassortment of novel viruses with the capacity to cause human pandemics5. Indeed, the 2009 H1N1 pandemic arose from a North American triple reassortant virus with genes derived from bird, swine and human flu viruses which further reassorted with a Eurasian pig flu virus5. The pandemic resulted in millions of hospitalizations and an estimated 300,000 deaths6. Although swine influenza is typically caused by only three subtypes of influenza A viruses, these continue to evolve at an ever increasing pace; in combination with the possibility of the introduction of a novel subtype into pigs, this raises the likelihood of more frequent pandemics in future.

The current leading strategy for controlling the spread of influenza and treating infected humans relies on administering neuraminidase (NA) inhibitors (NAI) as antiviral therapies. However, a major concern with NAIs is the evolution of virus mutants that develop drug resistance7,8,9,10,11. Moreover, to be effective, treatment with current NAIs such as Tamiflu® must occur within hours after symptoms develop for any effect. Other significant deficiencies include that they generally have a limited benefit for relieving flu symptoms, preventing infection, transmission or complications and they typically induce a relatively high rate of adverse drug reactions12,13. These shortcomings along with the low coverage of current vaccines require the urgent development of more effective approaches to counter future influenza outbreaks. One approach may be through targeting innate immune cells that can rapidly inhibit IAV replication and which are more refractory to resistance mechanisms of IAVs.

Invariant natural killer T (NKT) cells are a highly specialized subset of immune cells that share phenotypic and functional characteristics of both innate NK cells and adaptive T lymphocytes. These cells express a semi-invariant T cell receptor (TCR) that recognizes self and foreign glycolipid antigens presented by the non-polymorphic CD1d molecules on antigen presenting cells. Once activated, NKT-cells stimulate a diverse array of innate and adaptive immune responses important for controlling a wide range of infectious diseases14. We recently demonstrated that swine co-injected with the NKT-cell superagonist, α-galactosylceramide (α-GalCer), and a model antigen hen-egg lysozyme (HEL) generate strong antigen-specific T cell and antibody responses15. We also demonstrated that intramuscular (i.m.) immunization of UV-killed whole influenza virus pandemic H1N1 (pH1N1) (A/California/04/2009 [kCA04]) and α-GalCer is a safe and effective means of protecting against a homologous challenge with live virus16.

In the current work we extend these studies by showing that delivery of α-GalCer into the nasal passages of piglets infected with pH1N1 generates immunity that effectively inhibits viral replication in airway tissues and markedly decreases virus shedding. Most significantly, administration of α-GalCer to IAV-infected animals reduced disease severity and lung pathology, and did not cause any adverse immune reactions in young piglets. Our results demonstrate the possibility of using NKT-cell agonists to reduce the severity of influenza infections in swine, thereby limiting IAV transmission from pigs to humans. They also show potential for harnessing NKT-cell agonists for treating IAV infections in humans for which effective therapies are currently lacking.


α-GalCer reduces flu symptoms and restores weight gain in influenza-infected pigs

To determine whether α-GalCer mitigates influenza infections in swine, we compared the efficacy of α-GalCer delivered by the intranasal (i.n.) or i.m. routes for treating IAV-infected piglets. Accordingly, three-week-old commercial breed piglets were infected with a large inoculum (5 × 105 TCID50) of pandemic H1N1 (pH1N1) A/California/04/2009 (CA04) virus delivered directly into the lungs by intratracheal (i.t.) inoculation. At the same time, pigs were treated with either vehicle (Mock/CA04) or with 100 μg/kg α-GalCer injected into the neck muscle (IM αGC/CA04), or dripped into the nostrils (IN αGC/CA04). As a control, another group of pigs were mock infected and sham treated with vehicle (Mock/Mock). Characteristics of pigs in different treatment groups are described in Table 1.

Table 1: Characteristics of pigs enrolled in the experiment.

IN αGC/CA04 pigs did not develop diarrhea (0/3), in contrast to Mock/CA04 pigs (3/3) and IM αGC/CA04 pigs (2/3) (Fig. 1a). IN αGC/CA04 pigs also had reduced nasal discharge (Fig. 1b) and were more alert during the acute phase of infection (1–3 days post-infection [p.i.]) than pigs in the other CA04-infected groups. We observed some nasal discharge and diarrhea in control pigs on day 5 p.i. This was probably due to an unrelated infection, because control pig nasal secretions and respiratory tissues remained CA04 free for the duration of the experiment. We also measured weight gain as influenza infections reduce feed intake in pigs, which is of practical concern for swine producers. Without secondary disease, IAV infections seldom cause pigs to lose weight. In this respect, pigs are similar to humans and unlike mice that develop much more severe disease compared to natural host species as many strains express a functionally inactive form of the antiviral protein Mx117,18. Pigs that received α-GalCer i.n., but not i.m., achieved the same body weight gain (~10% of initial weight) as Mock/Mock pigs over the challenge period (Fig. 1c). Mock/CA04 pigs did not gain any weight. These results demonstrate that α-GalCer delivered by the i.n. route can alleviate the symptoms of a severe influenza infection.

Figure 1: Intranasal α-GalCer administration reduces flu symptoms and restores body weight gain in IAV-infected pigs.
Figure 1

(a,b) Health scores reported for individual pigs and mean ± standard error of the mean (SEM) for each treatment group on days 1, 2, 3 and 5 post infection (p.i.). (a) Fecal score: ranked from 0 to 3; 0: normal; 1: semi-solid; 2: liquid; 3: watery, presence of mucous or blood. (b) Nasal secretion: observed to be clear and serosa for all animals; ranked from 0 to 3, as 0: absent; 1: small volume discharge, from one nostril; 2: small volume, both nostrils; 3: large volume, both nostrils. (c) Percentage body weight gain compared to day −1 p.i. for SI virus-challenged pigs mock-treated with MEM (Mock/CA04) or treated with 100 μg/kg α-GalCer administered i.m. (IM αGC/CA04) or i.n. (IN αGC/CA04). Control pigs were mock challenged and mock-treated with MEM (Mock/Mock). Differences in weight gain were analyzed using the Kruskal-Wallis test. *P < 0.05. Data are represented as mean ± SEM.

α-GalCer administration during IAV challenge does not alter leukocyte populations in blood, lung or lymphoid tissues

There exist important safety concerns about using α-GalCer therapy during acute influenza infections because of the pro-inflammatory responses produced by activated NKT-cells. Therefore, we evaluated the effects of IAV infection and α-GalCer administration on leukocyte populations using flow cytometry (Fig. 2) in peripheral blood (PB) throughout the challenge period (Fig. 3) and in bronchoalveolar lavage fluid (BALF) (Table 2), lung (Table 3), tracheobronchial lymph nodes (TBLN) (Supplementary Table 1) and spleen (Supplementary Table 2) after euthanasia at 7 days p.i. No differences were detected amongst treatments for NKT-cell frequency or subsets based on expression levels of CD4, CD8α, CD11b, CD335 (Nkp46) and CD44. Also, no differences were found for the frequency of αβ T cells, γδ T cells, NK cells, monocytes and granulocytes in PB and for any of the respiratory and lymphoid tissues tested. One pig in the IM αGC/CA04 group expressed particularly high levels of NKT-cells (1.6% of CD3+ cells in blood) compared to other pigs enrolled in the experiment. This accounts for why the average NKT-cell frequency for the IM αGC/CA04 group was relatively high throughout the study. Our results suggest that NKT-cell activation during IAV infection mitigates disease without causing changes in immune cell populations that could be potentially harmful.

Figure 2: Gating strategy to identify immune cell populations in different swine tissues.
Figure 2

Single cell suspensions were labeled with PBS57-loaded and unloaded CD1d-tetetramer and various antibodies. (a) T cells were identified as CD3+ cells after first gating on single-celled, live lymphocytes according to size and granularity. NKT-cells were distinguished from conventional T cells according to CD1d-tetramer staining. NKT-cell and conventional T cell subsets were distinguished according to surface expression of CD4, CD8α, CD44, and CD11b. (b) NK cells were identified as CD8α+ CD3 cells after gating single live lymphocytes. Different NK cell subsets were distinguished from each other according to Nkp46 and CD11b surface expression (c) γδ T cells were identified as TCRδ+ CD3+ cells after gating on single-celled, live lymphocytes. (d) Monocytes and granulocytes were identified as CD172α+ cells with respectively high and low granularity according to side scatter. One representative lung sample is shown.

Figure 3: Frequency of immune cell populations analyzed from peripheral blood (PB) throughout the trial.
Figure 3

(a) NKT-cells as a proportion of CD3+ lymphocytes, (b) CD3+ cells as a proportion of lymphocytes, (c) CD4+ single positive T cells as a proportion of CD3+ lymphocytes, (d) CD8α+ single positive T cells as a proportion of CD3+ lymphocytes, (e) double positive CD4+ CD8α+ T cells as a proportion of CD3+ lymphocytes, (f) γδ T cells as a proportion of CD3+ lymphocytes, (g) NK cells (CD3 CD8α+) as a proportion of lymphocytes, (h) CD172α+ cells as a proportion of leukocytes. Differences in PB immune cell populations were analyzed using the SAS PROC MIXED procedure and no treatment differences were identified. Data are represented as mean ± SEM.

Table 2: Frequency of leukocyte populations in bronchoalveolar lavage fluid (BALF) at day 7 post infection.
Table 3: Frequency of leukocyte populations in lung tissue at day 7 post infection.

α-GalCer dramatically reduces viral replication in the respiratory tract and decreases nasal shedding

We investigated the ability of α-GalCer to reduce viral replication in the airway tissues and decrease viral shedding in nasal discharge. High viral titers were detected in lung tissue and BALF of pigs in the Mock/CA04 and IM αGC/CA04 treatment groups at day 7 p.i. (Fig. 4a,b). In striking contrast, viral titers were respectively >100 fold and >9,000 fold lower in lung tissue and BALF of IN αGC/CA04 pigs. Simultaneously, nasal shedding was drastically reduced in IN αGC/CA04 pigs that had >70,000 fold less virus in nasal swabs at day 2 p.i. compared to pigs in the other virus-infected groups (Fig. 4c). Furthermore, viral titers were reduced to almost undetectable levels in IN αGC/CA04 pigs (102 TCID50/ml) by 7 days p.i., but remained high in Mock/CA04 pigs (106 TCID50/ml). Taken together, these results indicate that α-GalCer administration via the i.n., but not the i.m. route, generates early innate immune responses that significantly inhibits viral replication, even though piglets were infected with a high dose of CA04 virus delivered directly into the lungs.

Figure 4: Intranasal but not intramuscular administration of α-GalCer inhibits viral replication in respiratory tissues and reduces nasal shedding in pigs challenged with CA04 virus.
Figure 4

Viral titers for (a) homogenized airway tissues and (b) bronchoalveolar lavage fluid (BALF) collected at 7 days p.i. as well as (c) nasal swabs collected at −1, 1, 2, 3, 5 and 7 days p.i. Changes in nasal swab titers were analyzed using the SAS PROC MIXED procedure and the Turkey’s test was used to examine treatment differences at each time point for each dependent variable. Changes in BALF and airway tissue titers were analyzed using the Kruskal-Wallis test. *P < 0.05. Data are represented as mean ± SEM.

Activating NKT-cells during an influenza infection reduces lung pathology

The decreased viral shedding and replication observed in i.n. α-GalCer treated piglets were also supported by histopathological analysis of lung sections. As shown, Mock/CA04 infected and i.m. α-GalCer treated animals developed severe pulmonary edema and peribronchiolar and perivascular inflammation (Fig. 5a,b). The degree of bronchiolar epithelial hyperplasia and airway narrowing was moderate to severe, with multiple bronchioles being affected. In contrast, lung sections from i.n. α-GalCer treated piglets had considerably fewer infiltrating cells around the bronchioles and blood vessels and relatively normal bronchial epithelium. Collectively, our data show that i.n. administration of α-GalCer dramatically reduced CA04-induced histopathological alterations in the lungs.

Figure 5: Intranasal treatment with α-GalCer reduces influenza induced lung inflammation and pathology.
Figure 5

Lung inflammation and pathology was assessed by H&E staining on day 7 post-infection with CA04. (a) Four representative micrographs for the indicated treatment groups are shown. (b) Bronchioles in lung sections were graded by light microscopy on an arbitrary scale from 1–5 for inflammation severity; 1 = a small number of inflammatory foci and 5 = a large and widespread infiltrate, more than three cells deep. The number of bronchioles scored from each treatment was 22 for Mock/Mock, 142 for Mock/CA04, 97 for IM αGC/CA04 and 81 for IN αGC/CA04.


Our results show for the first time that administration of α-GalCer into the nasal passages of newly-weaned piglets significantly reduces flu symptoms and generates protective immunity that inhibits IAV replication in airway tissues, markedly decreasing viral shedding and lung pathology without any noticeable adverse effects. Our results were much better than a recent publication showing that Tamiflu, a NAI that is the leading influenza treatment for humans, has no effect on viral replication in lungs of influenza infected pigs and has little impact on nasal shedding19. An important advantage of NKT-cell superagonists over NAIs is that they are likely to remain an effective therapy for treating influenza even with extensive use over time. This is because activated NKT-cells provide protection that is mediated through an array of cell types and cytokines that directly and indirectly inhibit viral replication20. Since it is more difficult for pathogens to simultaneously develop resistance to multiple pathways than to a single pathway, the likelihood of influenza viruses becoming resistant to NKT-cell superagonists is low.

The current work also represents a first attempt to exploit NKT-cell therapy to counteract influenza in a natural host species capable of producing zoonotic infections, rather than experimental animal models. Two previous murine studies showed that α-GalCer administered by intraperitoneal (i.p.) injection increased survival in mice infected with a lethal dose of the IAV A/PR8/3421,22. A third study found that weight profile and viral titers improved in mice infected with a non-lethal dose of the human IAV E61-13-H17 when α-GalCer was administered i.p., but not through the intranasal route23. These reports support that α-GalCer is capable of reducing infections by different IAV strains in different genetic backgrounds. However, mice are limited for modeling IAV infections because they are generally resistant to primary human influenza isolates24. Conversely, when mouse-adapted influenza viruses are used, inbred mice usually develop much more severe disease compared to pigs and humans as many strains express a functionally inactive form of the antiviral protein Mx117,18. Mice also have drawbacks for modeling NKT-cell immunotherapy because murine NKT-cell frequencies, subsets and tissue localization patterns differ considerably compared to pigs and humans15,16,25,26.

The mechanisms underlying α-GalCer-mediated influenza protection in swine remain unclear. Our study did not detect changes in the frequency of immune cells when pigs were euthanized at a late time point after challenge and treatment (7 days p.i). Uncertainty also remains about how NKT-cell agonists clear influenza infections in mice. Ho et al. found that protection was associated with a rapid and transient increase in chemo-attractive cytokines after α-GalCer administration followed by the influx of infiltrating neutrophils and monocytes into the lung that potentially clear virus infected epithelial cells23. Kok et al. showed that NKT-cell activation did not affect virus load but rather prevented lung injury by reducing the number of inflammatory monocytes in the respiratory tract following infection21. De Santo et al. reported that α-GalCer-activated NKT-cells decrease the accumulation of immunosuppressive myeloid-derived suppressor cells, which suppress IAV-specific immune responses in the lung through the expression of nitric oxide synthase and arginase27. To identify whether similar immune mechanisms contribute to protecting pigs from influenza infections, future studies should examine porcine NKT-cells and NKT-transactivated cell types within 48 hours after treatment with α-GalCer. Of interest will be whether NKT-cell-mediated IAV immunity is the same between swine and mice given that α-GalCer only protects pigs and mice when delivered via the intranasal and systemic routes, respectively. Also of practical interest will be whether NKT-cell agonists can clear influenza infections after symptoms appear.

Although additional mechanistic studies are needed, our findings provide proof-of principal that NKT-cell agonists could prove a potent strategy for improving the course of disease in swine as well as humans with seasonal and pandemic influenza infections. If successful, this approach has potential for reducing zoonotic IAV infections between swine and people that sometimes give rise to strains capable of causing pandemics. They also provide a clear rational for using NKT-cell agonists to target other microbial pathogens that threaten pig and human health.



Piglets were a cross between Hampshire, Yorkshire, Chester White, Duroc, and Landrace breeds from the University of Florida swine unit. Experiments were performed in compliance with regulations from the National Research Council’s Guide for the Care and Use of Laboratory Animals, the United States Department of Agriculture and all relevant state and federal regulations and policies. The animal care and use committee at the University of Florida approved the protocol under the project number 201308209.

Experimental design

At two-weeks of age piglets were bled from the jugular vein to measure their peripheral blood (PB) NKT-cell frequencies. Eleven piglets were selected and assigned to one of four groups so that each group contained pigs with a similar range of NKT-cell frequencies (Table 1). All animals were confirmed seronegative for antibodies against H1N1, H3N2 and B viruses by hemagglutination inhibition assays (HAI) as described16. At 4 weeks of age, piglets in group 1 were intratracheally sham-infected with virus-free MEM media while groups 2–4 were challenged with 105 TCID50 CA04 as described before16. At the same time, piglets in groups 1–2 were administered 2 ml PBS containing 2% DMSO i.n. and piglets in groups 3–4 were administered 100 μg/kg α-GalCer dissolved in 2 ml PBS that was respectively injected into the neck muscle (i.m.) and dripped into the nostrils (i.n.). Stock solutions of α-GalCer were prepared in DMSO as previously described15. Control pigs were housed separately from CA04 animals.

During the 7-day challenge period, piglets were monitored daily for disease symptoms, including body weight, dyspnea, coughing, sneezing, nasal discharge, ocular discharge, eye redness and diarrhea. Nasal secretions were scored from 0 to 3, as 0: absent; 1: small volume discharge, from one nostril; 2: small volume, both nostrils; 3: large volume, both nostrils19,28. Fecal score was ranked from 0 to 3, as 0: normal; 1: semi-solid; 2: liquid; 3: watery, presence of mucous or blood29,30. Blood samples were collected at −1, 1, 2, 5 and 7 days p.i. for analysis of immune cell populations. Nasal swabs were collected at −1, 1, 2, 3, 5 and 7 days p.i. to measure viral titers. Pigs were euthanized at 7 days p.i. and tissue were collected from lung and trachea to determine viral titers. Tissue samples were also collected from lung, spleen and tracheobronchial lymph nodes (TBLN) for analysis by flow cytometry and histopathology. Bronchoalveolar lavage fluid (BALF) was collected at necropsy by lavaging the left lung with 35 ml of MEM for analysis of immune cell subsets and viral titers16.

Flow cytometry and antibodies

Blood samples were collected from the jugular vein in heparinized vacutainer tubes (BD Biosciences, San Jose, CA). Spleen and lymph node tissues were dispersed into single cells as previously described15. Lung tissues (0.5 grams of tissue) were minced using scissors, digested with 300 μg Liberase TL (Sigma-Aldrich, Saint Louis, MO) at 37 °C for 45 minutes and filtered through 70 μm cell strainers (Falcon BD Labware, Bedford, MA). BALF was collected as described before16. An ammonium chloride-based lysis buffer was used to eliminate residual red blood cells from tissue samples and PB. Leukocyte populations were characterized using BD Accuri C6 and BD LSRFortessa flow cytometers (BD Bioscience) after cells were blocked and stained as previously described16,31. Staining strategies, NKT-cell tetramer reagents and antibodies used to assess NKT-cells, conventional αβ T cells, γδ T cells, monocytes and granulocytes are described in Fig. 2 and Supplemental Table 3. Data were analyzed using FlowJo software (Treestar, Palo Alto, CA).

Virus and viral titers

Influenza virus encoding the original consensus sequence of the H1N1pdm09 strain A/California/04/2009 (CA04) was generated and recovered as previously described5,16. Viral titers were calculated from the median TCID50, and viral titers expressed as TCID50/ml, TCID50/gm, or their Log10-transformed values, as appropriate32,33. TCID50 values were determined by infecting MDCK cells in 96-well microtiter plates with serial dilutions of virus. Five days later the TCID50 was calculated according to the method of Reed and Muench34.

Lung histology

At day 7 post infection, lung tissues were collected from Mock/Mock, Mock/CA04, IM α-GalCer/CA04 and IN α-GalCer/CA04 treated piglets, fixed in 10% zinc-buffered formalin, embedded in paraffin, and 5 μm thick sections were cut and stained with hematoxylin and eosin (H&E) as described before35. A previously described semiquantitative scoring system was used to grade the size of lung infiltrates, where 5 signified a large (more than three cells deep) widespread infiltrate around the majority of vessels and bronchioles, and 1 signified a small number of inflammatory foci36.

Statistical analysis

The data were analyzed with the PROC MIXED procedure of SAS (v9.3, SAS Institute Inc., Cary, NC) when established to be normally distributed according to the QQPLOT procedures. Autoregressive covariance structure was applied to evaluate treatment effects on changes in nasal swab viral titers, after log transformation. Means were separated using Turkey’s test when a main effect or interaction term was determined to be significant (P < 0.05). Immune cell populations in blood during infection challenge were evaluated using PROC GLM of SAS. Least square means was used to determine significant difference (P < 0.05) between treatments.

Data for disease symptoms, body weight change and tissue viral titers were not normally distributed and analyzed using a nonparametric Kruscal-Wallis test with GraphPad Prism (version 6.0 h for Macintosh, GraphPad Software Inc., La Jolla, CA). Means were separated using Dunn’s multiple comparisons test when a main effect or interaction term was determined to be significant (P < 0.05). Linear regression analyses were preformed using GraphPad Prism.

Additional Information

How to cite this article: Artiaga, B. L. et al. Rapid Control of Pandemic H1N1 Influenza by Targeting NKT-cells. Sci. Rep. 6, 37999; doi: 10.1038/srep37999 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    et al. Review of influenza A virus in swine worldwide: a call for increased surveillance and research. Zoonoses Public Health 61, 4–17, doi: 10.1111/zph.12049 (2014).

  2. 2.

    et al. Production impact of influenza A(H1N1)pdm09 virus infection on fattening pigs in Norway. J Anim Sci 94, 751–759, doi: 10.2527/jas.2015-9251 (2016).

  3. 3.

    , , & The role of swine as “mixing vessel” for interspecies transmission of the influenza A subtype H1N1: a simultaneous Bayesian inference of phylogeny and ancestral hosts. Infect Genet Evol 11, 437–441, doi: 10.1016/j.meegid.2010.12.001 (2011).

  4. 4.

    & Swine influenza vaccines: current status and future perspectives. Anim Health Res Rev 11, 81–96, doi: 10.1017/S146625231000006X (2010).

  5. 5.

    et al. The neuraminidase and matrix genes of the 2009 pandemic influenza H1N1 virus cooperate functionally to facilitate efficient replication and transmissibility in pigs. J Gen Virol 93, 1261–1268, doi: 10.1099/vir.0.040535-0 (2012).

  6. 6.

    et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12, 687–695, doi: 10.1016/S1473-3099(12)70121-4 (2012).

  7. 7.

    et al. Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009–2011. J Med Virol 85, 379–387, doi: 10.1002/jmv.23482 (2013).

  8. 8.

    et al. Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada. Influenza Other Respir Viruses, doi: 10.1111/irv.12415 (2016).

  9. 9.

    et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill 21, doi: 10.2807/1560-7917.ES.2016.21.24.30258 (2016).

  10. 10.

    et al. Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid. J Virol 90, 4637–4646, doi: 10.1128/JVI.00013-16 (2016).

  11. 11.

    et al. Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China. Virol J 12, 96, doi: 10.1186/s12985-015-0317-1 (2015).

  12. 12.

    et al. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. Influenza Other Respir Viruses 7 Suppl 2, 76–81, doi: 10.1111/irv.12085 (2013).

  13. 13.

    et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348, g2545 (2014).

  14. 14.

    , , & CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system. Current opinion in immunology 20, 358–368, doi: 10.1016/j.coi.2008.03.018 (2008).

  15. 15.

    , , & Adjuvant effects of therapeutic glycolipids administered to a cohort of NKT cell-diverse pigs. Vet Immunol Immunopathol 162, 1–13, doi: 10.1016/j.vetimm.2014.09.006 (2014).

  16. 16.

    et al. α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant. Sci Rep 6, 23593, doi: 10.1038/srep23593 (2016).

  17. 17.

    et al. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci USA 104, 6806–6811, doi: 10.1073/pnas.0701849104 (2007).

  18. 18.

    et al. The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol 81, 10818–10821, doi: 10.1128/JVI.01116-07 (2007).

  19. 19.

    et al. Efficacy of influenza vaccination and tamiflu® treatment–comparative studies with Eurasian Swine influenza viruses in pigs. PLoS One 8, e61597, doi: 10.1371/journal.pone.0061597 (2013).

  20. 20.

    , & The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity? J Leukoc Biol 88, 635–643, doi: 10.1189/jlb.0410191 (2010).

  21. 21.

    et al. Pivotal Advance: Invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection. J Leukoc Biol 91, 357–368, doi: 10.1189/jlb.0411184 (2012).

  22. 22.

    et al. IFN-γ production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells. Virology 407, 325–332, doi: 10.1016/j.virol.2010.08.030 (2010).

  23. 23.

    et al. Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur J Immunol 38, 1913–1922, doi: 10.1002/eji.200738017 (2008).

  24. 24.

    & Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses 2, 1530–1563, doi: 10.3390/v20801530 (2010).

  25. 25.

    , & Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res 343, 43–55, doi: 10.1007/s00441-010-1023-3 (2011).

  26. 26.

    , & The biology of NKT cells. Annu Rev Immunol 25, 297–336, doi: 10.1146/annurev.immunol.25.022106.141711 (2007).

  27. 27.

    et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 118, 4036–4048, doi: 10.1172/JCI36264 (2008).

  28. 28.

    & Respiratory disease of the bovine neonate. Vet Clin North Am Food Anim Pract 25, 121–137, vi–vii, doi: 10.1016/j.cvfa.2008.10.007 (2009).

  29. 29.

    et al. Reproduction of mucohaemorrhagic diarrhea and colitis indistinguishable from swine dysentery following experimental inoculation with “Brachyspira hampsonii” strain 30446. PloS one 8, e57146, doi: 10.1371/journal.pone.0057146 (2013).

  30. 30.

    et al. Investigation of the impact of increased dietary insoluble fiber through the feeding of distillers dried grains with solubles (DDGS) on the incidence and severity of Brachyspira-associated colitis in pigs. PloS one 9, e114741, doi: 10.1371/journal.pone.0114741 (2014).

  31. 31.

    et al. Targeted disruption of CD1d prevents NKT cell development in pigs. Mamm Genome 26, 264–270, doi: 10.1007/s00335-015-9564-0 (2015).

  32. 32.

    et al. Ferrets develop fatal influenza after inhaling small particle aerosols of highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1). Virol J 7, 231, doi: 10.1186/1743-422X-7-231 (2010).

  33. 33.

    et al. Higher titers of some H5N1 and recent human H1N1 and H3N2 influenza viruses in Mv1 Lu vs. MDCK cells. Virol J 8, 66, doi: 10.1186/1743-422X-8-66 (2011).

  34. 34.

    & A simple method for estimating fifty percent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).

  35. 35.

    et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 198, 315–324, doi: 10.1084/jem.20021937 (2003).

  36. 36.

    , , , & Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase C theta. J Immunol 173, 6440–6447 (2004).

Download references


We thank the NIH Tetramer Core Facility (contract HHSN272201300006C) for provision of the CD1d tetramers. This work was supported by the University of Florida’s Research Opportunity Seed Fund and the University of Florida’s Institute for Food and Agricultural Sciences (IFAS) Early Career Award to J.D., the National Institutes of Health under contract number HHSN266200700005C to J.R., and AI087734 to S.S.-A. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author information

Author notes

    • Bianca L. Artiaga
    •  & Guan Yang

    These authors contributed equally to this work.


  1. Department of Animal Science, University of Florida, Gainesville, FL, USA

    • Bianca L. Artiaga
    • , Guan Yang
    •  & John P. Driver
  2. Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA

    • Tarun E. Hutchinson
    •  & Shahram Salek-Ardakani
  3. Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA

    • Julia C. Loeb
    •  & John A. Lednicky
  4. Diagnostic Medicine and Pathobiology and Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA

    • Jürgen A. Richt
  5. Department of Environmental and Global Health, University of Florida, Gainesville, FL, USA

    • John A. Lednicky


  1. Search for Bianca L. Artiaga in:

  2. Search for Guan Yang in:

  3. Search for Tarun E. Hutchinson in:

  4. Search for Julia C. Loeb in:

  5. Search for Jürgen A. Richt in:

  6. Search for John A. Lednicky in:

  7. Search for Shahram Salek-Ardakani in:

  8. Search for John P. Driver in:


B.A. and G.Y. designed, performed and analyzed the experiments, interpreted the data and wrote the manuscript. T.H. and J.C.L. performed and analyzed the experiments. J.R. provided virus plasmids and contributed to the discussion. J.A.L. performed and analyzed the experiments, interpreted the data and contributed to the discussion. J.D. and S.S.-A. directed the research and wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to John P. Driver.

Supplementary information

About this article

Publication history






By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.